Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and the
World Boxing Council (“WBC”) announced today that Sorrento’s
COVI-STIX COVID-19 Virus Rapid Antigen Detection Test (“COVI-STIX”)
will be used for screening all attendees of the upcoming 59th World
Boxing Council Annual Convention in Mexico City, Mexico (November
14th through November 18th).
The pandemic brought the world to a standstill
and while most sports froze, boxing remained active through efforts
by promoters, boxing commissions and the WBC. Boxing leads the
world of sports in administrative and medical protocols to allow
boxing matches to be held in bubbles without fans present.
Testing is and should remain a major factor for
the successful organization of any public event, including boxing
events with audiences present at maximum capacity.
Sorrento Therapeutics Mexico has teamed with the
WBC to provide COVI-STIX rapid testing for the event and have
together committed to be very active in providing solutions to the
boxing industry, as well as other sports and entertainment focused
events.
COVI-STIX tests will be administered to all
convention attendees prior to registration and a local testing
laboratory will provide testing and travel certificates to all
foreign visitors requiring proof of testing for international
travel.
Many superstars will be in Mexico City to attend
the “Together Again” convention, including Floyd Mayweather, Julio
César Chávez, Oscar De La Hoya, Larry Holmes, Roberto Durán and
Antonio Tarver, among many other heroes from yesterday and today
who will be in attendance, including boxing’s biggest superstar
Canelo Álvarez.
For information regarding the WBC convention,
please refer to WBC’s website at
https://wbcboxing.com/en/info-about-wbc-convention-59/ or send an
email to contact@wbcboxing.com.
About Sorrento Therapeutics, Inc.
Sorrento is a clinical and commercial stage
biopharmaceutical company developing new therapies to treat cancer,
pain (non-opioid treatments), autoimmune disease and COVID-19.
Sorrento's multimodal, multipronged approach to fighting cancer is
made possible by its extensive immuno-oncology platforms, including
key assets such as fully human antibodies (“G-MAB™ library”),
immuno-cellular therapies (“DAR-T™”), antibody-drug conjugates
(“ADCs”), and oncolytic virus (“Seprehvec™”). Sorrento is also
developing potential antiviral therapies and vaccines against
coronaviruses, including Abivertinib, COVIGUARD™, COVI-AMG™,
COVISHIELD™, COVI-MSC™ and COVIDROPS™; and diagnostic test
solutions, including COVITRACK™, COVISTIX™ and COVITRACE™.
Sorrento's commitment to life-enhancing
therapies for patients is also demonstrated by our effort to
advance a first-in-class (TRPV1 agonist) non-opioid pain management
small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg,
dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel,
viscous gel formulation of a widely used corticosteroid for
epidural injections to treat lumbosacral radicular pain, or
sciatica, and to commercialize ZTlido® (lidocaine topical system)
1.8% for the treatment of post-herpetic neuralgia. RTX has
completed a Phase IB trial for intractable pain associated with
cancer and a Phase 1B trial in osteoarthritis patients. SEMDEXA is
in a pivotal Phase 3 trial for the treatment of lumbosacral
radicular pain, or sciatica. ZTlido® was approved by the FDA on
February 28, 2018.
For more information visit
www.sorrentotherapeutics.com.
About the World Boxing Convention (WBC)
The WBC Convention is the largest boxing
convention in the world. The great and the good from every aspect
of the sport attend, from boxers to referees judges, promoters,
managers doctors and many more.
The annual convention unites delegates from all
member-countries and key boxers from all over the world. During the
convention, participants discuss topical issues, plans and future
fights. Current champions often find out their rivals and the
candidates for the championship title.
Rules are reviewed and grievances are heard. The
convention deals with the previous 12 months and the next 12 months
and all the issues of the day are heard and discussed during open
sessions in a transparent and democratic process.
The World Boxing Council Convention is guided by
the WBC Board of Governors from all of the World Regions and its
president, Mauricio Sulaiman.
For more information, visit
www.wbcboxing.com.
Forward-Looking Statements
This press release and any statements made for
and during any presentation or meeting contain forward-looking
statements related to Sorrento Therapeutics, Inc., under the safe
harbor provisions of Section 21E of the Private Securities
Litigation Reform Act of 1995 and subject to risks and
uncertainties that could cause actual results to differ materially
from those projected. Forward-looking statements include statements
regarding COVI-STIX; the performance capabilities of COVI-STIX; the
planned use of COVI-STIX to screen convention attendees at the
World Boxing Council Convention; and Sorrento’s potential position
in the diagnostics industry. Risks and uncertainties that could
cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements, include, but are
not limited to: risks related to Sorrento’s and its subsidiaries’,
affiliates’ and partners’ technologies and prospects and
collaborations with partners, including, but not limited to risks
related to COVI-STIX; risks of manufacturing and supplying
COVI-STIX; risks related to leveraging the expertise of its
employees, subsidiaries, affiliates and partners to assist the
company in the execution of its COVID-19 product candidates’
strategies; risks related to the global impact of COVID-19; and
other risks that are described in Sorrento's most recent periodic
reports filed with the Securities and Exchange Commission,
including Sorrento's Annual Report on Form 10-K for the year ended
December 31, 2020, and subsequent Quarterly Reports on Form 10-Q
filed with the Securities and Exchange Commission, including the
risk factors set forth in those filings. Investors are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date of this release and we undertake no
obligation to update any forward-looking statement in this press
release except as required by law.
Media and Investor Relations
ContactDorman FollowwillEmail:
mediarelations@sorrentotherapeutics.com
Sorrento® and the Sorrento logo are registered
trademarks of Sorrento Therapeutics, Inc.
G-MAB™, DAR-T™, SOFUSA™, COVIGUARD™, COVI-AMG™,
COVISHIELD™, COVIDROPS™, COVI-MSC™, COVITRACK™, COVITRACE™ and
COVI-STIX™ are trademarks of Sorrento Therapeutics, Inc.
SEMDEXA™ is a trademark of Semnur
Pharmaceuticals, Inc.
ZTlido® is a registered trademark owned by
Scilex Pharmaceuticals Inc.
All other trademarks are the property of their
respective owners.
©2021 Sorrento Therapeutics, Inc. All Rights
Reserved.
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Apr 2023 to Apr 2024